[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Journal Information::
Articles archive::
For Authors::
For Reviewers::
Contact us::
Site Facilities::
Impact Factor 2022: 1.4
Cite Score 2022: 2.1
SJR 2022: 0.347
SNIP 2022: 0.545
Publication Charge
►Publication Fee
In Press
 In Press Articles
Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
:: Volume 10, Issue 2 (3-2019) ::
Caspian J Intern Med 2019, 10(2): 211-216 Back to browse issues page
Levofloxacin-containing triple therapy versus bismuth-based quadruple therapy as regimens for second line anti- Helicobacter pylori
Mohammadreza Seyyedmajidi , Laleh Abbasi , Seyedali Seyyedmajidi , Seyed Ashkan Hosseini , Anahita Ahmadi , Shahin Hajiebrahimi , Jamshid Vafaeimanesh
Gastrointestinal and Liver Diseases Research Center, Iran University of Medical Sciences, Tehran, Iran , jvafaeemanesh@yahoo.com
Abstract:   (6204 Views)
Background: Although the prevalence of Helicobacter pylori infection decreased following the hygiene promotion and application of proper anti- H.pylori treatments, unfortunately gradual increase is reported in treatment failure; hence, application of a proper treatment regimen as a second-line therapy is of great importance.
Methods: In the current randomized, clinical trial, a total of 120 patients with peptic ulcers who failed to respond to treatment were enrolled. In the OLA group, a regimen of omeprazole 40 mg/day, levofloxacin 1 g/day, and amoxicillin 2 g/ day was prescribed; however, a regimen of omeprazole 40 mg/day, bismuth sub-citrate 480 mg/day, furazolidone 400 mg/day, and amoxicillin 2 g/day was administered to the OFAB group. Both groups were treated for 2 weeks, and 6 weeks after the treatment, the urea breath test (UBT) was performed in the subjects. Collected data were analyzed with SPSS Version 18. At the end, 58 patients in group OLA and 57 patients in the OFAB group were analyzed.
Results: According to the results of the current study, 96.7% of the subjects in the OLA and 95% in the OFAB groups completed the treatment course and the eradication rates were 86.7% and 78.3% in the OLA and OFAB groups, respectively (P=0.23). Treatment side effects were observed in 51.7% and 11.7% of the subjects in the OLA and OFAB groups, respectively (P<0.01).
Conclusion: Both regimens were applicable as the second-line therapy due to insignificant difference between the results of the 2 groups; however, OLA regimen was superior to OFAB, due to lower side effects.

Keywords: Helicobacter pylori, Second-line Therapy, Levofloxacin, Furazolidone, Amoxicillin, Bismuth Sub-Citrate
Full-Text [PDF 372 kb]   (1193 Downloads)    
Type of Study: Original Article | Subject: Gastroentrology
Received: 2018/02/26 | Accepted: 2018/12/30 | Published: 2019/05/13
Send email to the article author

Add your comments about this article
Your username or Email:


XML     Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Seyyedmajidi M, Abbasi L, Seyyedmajidi S, Hosseini S A, Ahmadi A, Hajiebrahimi S et al . Levofloxacin-containing triple therapy versus bismuth-based quadruple therapy as regimens for second line anti- Helicobacter pylori. Caspian J Intern Med 2019; 10 (2) :211-216
URL: http://caspjim.com/article-1-1408-en.html

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 10, Issue 2 (3-2019) Back to browse issues page
Caspian Journal of Internal Medicine
Persian site map - English site map - Created in 0.06 seconds with 40 queries by YEKTAWEB 4639